Selamettin Demir

Selamettin Demir

Auto-generated profile, based on publicly available information

Selamettin Demir

Van Regional Training and Research Hospital

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2021 in Andrologia
Verified
Journal Article
Closed access
PDF file
SDSelamettin Demir
Selamettin Demir
IBİrfan Şafak Barlas
İrfan Şafak Barlas
Research has found that, instead of passive lipid‐accumulated vascular damage, atherosclerosis which is the primary cause of erectile dysfunction (ED) can be seen as an active inflammatory cycle and that inflammation has a central role in the entire atherosclerotic process. As an inflammatory marker, serum C‐reactive protein (CRP)/albumin ratio (CAR) may link to ED and ED severity. The CAR, demographic features and other criteria of 198 patients with ED who visited our outpatient clinic during March 2019–April 2020 were prospectively evaluated. The research also included healthy control subjects without systemic or infectious diseases. The mean difference of CAR between ED and no ED was statistically significant (0.55 ± 0.27 and 0.79 ± 0.49, p = .002 respectively). On the basis of the ROC analysis, CAR has a good ED diagnostic value with an area under the curve (AUC) of 0.63 (95% CI:0.541–0.714) and better diagnostic performance to distinguish ED severity (AUC:0.73, 95% CI:0.620–0.842). Additionally, mean CAR gradually increased with increasing severity of ED (for all p < .001). The CAR has been described as an independent ED indicator in the multivariate analysis (p = .001OR = 8.934; 95% CI:2.449–32.583). Increased CAR is associated with ED severity and increased ED risk. For CAR predicting ED and ED severity, a considerable cut‐off point was identified.

Verified
Journal Article
Open access
PDF file
SDSelamettin Demir
Selamettin Demir
Objectives: Although cancer is believed to develop and progress with the involvement of inflammation, it is still unclear what the correlation between inflammation and prostate cancer is. This study based on results of transrectal ultrasound-guided prostate biopsies aimed to determine whether C-reactive protein (CRP) and sterile pyuria were clinically useful in the evaluation of patients with suspect of prostate cancer. Materials and methods: This study is a cross-sectional prospective study of patients without clinical prostatitis symptoms. Characteristics of the 200 consecutive patients recruited were 3-20 ng/mL value of serum prostate-specific antigen (PSA), normal digital rectal examination finding, and sterile urine culture result. All patients underwent 12-core prostatic biopsy. 163 of the 200 patients had benign prostatic hyperplasia confirmed through histology, while the residual 37 patients had prostate cancer. Patients with pre-treatment urinary leukocyte count ≤ 3/high power field were categorized as non-pyuria, whilst those with pre-treatment urinary leukocyte count > 3/high power field were categorized as pyuria. The serum CRP level was also used to differentiate patients before the biopsy. Subgroups were compared regarding a number of clinical variables. Results: Histology revealed that 70% of pyuria patients and 38.5% of non-pyuria patients presented inflammation (p = 0.001). The pyuria group exhibited significantly higher total PSA compared to the non-pyuria group (p = 0.044). The two groups did not differ significantly regarding cancer detection rate (p = 0.752). CRP groups were similar regarding cancer detection and histologically-detected inflammation rates. Conclusion: In patients with no evidence of clinical prostatitis, sterile pyuria should be considered as a cause of increased PSA. Although sterile pyuria cannot predict non-palpable prostate cancer, it should be taken into account in urological evaluation in order to demonstrate minute prostatic inflammation due to its simplicity, convenience and non-invasiveness.


Verified
Journal Article
Open access
PDF file
EBErdal Benli
Erdal Benli
AÇAbdullah Çırakoglu
Abdullah Çırakoglu
EÖErcan Ögreden
Ercan Ögreden
SDSelamettin Demir
Selamettin Demir
YKYasemin Kaya
Yasemin Kaya
AYAhmet Yüce
Ahmet Yüce
Aim: The aim of this study was to investigate whether there is a relationship between erectile dysfunction (ED), thought to be a vascular disease, and AB0 blood group. Material and Method: The study included 350 people abiding by the study criteria who applied to our clinic from April 2012-April 2015. The patients were divided into two groups including those with ED (Group 1) and those without (Group 2). Age, blood group, IIEF-5 score and presence of additional diseases were recorded. Erectile functions were analyzed according to blood group. Results: There was no difference between the mean age of 111 patients with ED and that of 239 patients without ED included in the study (p = 0.284). There was no difference between patients in the two groups in terms of smoking, alcohol use, hypertension and diabetes (p > 0.05). Among patients in the ED group, the mean IIEF-5 score according to blood group was 19.8 ± 5.04 in the 0 blood group, 16.5 ± 5.2 in the A blood group, 17.2 ± 5.3 in the B blood group and 13.3 ± 3.02 in the AB blood group. The IIEF-5 scores of individuals in the 0 blood group were significantly high compared to individuals in other blood groups (p = 0.004). Logistic regression analysis found that compared to the 0 blood group, the erectile dysfunction risk was 3.9 times greater for the A blood group, 3.5 times greater for the B blood group and 4.7 times greater for the AB blood group (p = 0.001) (Table 3). Conclusion: The risk of erectile dysfunction was significantly increased for individuals in the A, B and AB blood groups compared to individuals in the 0 blood group.

28 May 2024
Verified
Book Chapter
Closed access
MAMustafa Kaan Akalin
Mustafa Kaan Akalin
SDSelamettin Demir
Selamettin Demir
In this section, NMIBC constitutes the majority of bladder cancer cases, characterized by a favorable prognosis. Recurrence and progression rates vary widely, highlighting the chronic nature of NMIBC and the need for extensive follow-up and treatment sessions. Various prognostic factors influence recurrence and progression, including tumor characteristics and patient demographics. Risk stratification tools like the EORTC and CUETO calculators aid in predicting probabilities at different time points, although current models have limitations. Factors like smoking and genetic alterations contribute to recurrence and progression risk. However, there’s a call for more efficient risk stratification tools incorporating new biomarkers and treatment strategies to enhance patient management.

27 May 2021
Verified
Book
Open access
PDF file
ZCZeynel Canoğulları
Zeynel Canoğulları
MDMesut Berkan Duran
Mesut Berkan Duran
SYSercan Yılmaz
Sercan Yılmaz
CÖCihat Özcan
Cihat Özcan
YKYalçın Kızılkan
Yalçın Kızılkan
YAYasemin Alan
Yasemin Alan
Bu üründe yer alan bilgiler sadece lisanslı tıbbi